Onestream Inc(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OS Onestream Inc

Closed 11-12 16:00:00 EST

33.50

-0.83

-2.42%

盘后32.06

-1.44-4.30%

19:42 EST

High34.60	Low32.65	Vol1.08M
Open34.25	D1 Closing34.33	Amplitude5.68%
Mkt Cap5.37B	Tradable Cap938.78M	Total Shares160.38M
T/O36.11M	T/O Rate3.84%	Tradable Shares28.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":33.5,"timestamp":1731445200000,"preClose":34.33,"halted":0,"volume":1075375,"hourTrading":{"tag":"盘后","latestPrice":32.0606,"preClose":33.5,"latestTime":"19:42 EST","volume":11961,"amount":389620.39,"timestamp":1731458540374},"delay":0,"floatShares":28023303,"shares":160383087,"eps":-1.135048,"marketStatus":"Closed","change":-0.83,"latestTime":"11-12 16:00:00 EST","open":34.25,"high":34.6,"low":32.65,"amount":36111144.118,"amplitude":0.056802,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.135048,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731488400000},"marketStatusCode":5,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":34.33,"preHourTrading":{"tag":"盘前","latestPrice":34.33,"preClose":34.33,"latestTime":"08:08 EST","volume":103,"amount":3535.99,"timestamp":1731416914515},"postHourTrading":{"tag":"盘后","latestPrice":32.0606,"preClose":33.5,"latestTime":"19:42 EST","volume":11961,"amount":389620.39,"timestamp":1731458540374},"volumeRatio":0.74515,"impliedVol":0.4432,"impliedVolPercentile":0.3067},"requestUrl":"/m/hq/s/OS/tweets","defaultTab":"tweets","newsList":[{"id":"2483067578","title":"BRIEF-Colby Craig Reports 30.7% Passive Stake In Onestream As Of Sept 30- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483067578","media":"Reuters","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483067578?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:35","pubTimestamp":1731454507,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - OneStream Inc   :   * COLBY CRAIG REPORTS 30.7% PASSIVE STAKE IN ONESTREAM AS OF SEPT 30- SEC FILINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2483594062","title":"BRIEF-Onestream Announces Launch Of Secondary Offering Of Class A Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2483594062","media":"Reuters","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483594062?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:23","pubTimestamp":1731453792,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - OneStream Inc   :   * ONESTREAM ANNOUNCES LAUNCH OF SECONDARY OFFERING OF CLASS A COMMON STOCK   * ONESTREAM INC - ANNOUNCES PUBLIC OFFERING OF 15 MILLION CLASS A SHARESSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2483643260","title":"Colby Craig Reports 30.7% Passive Stake in Onestream as of Sept 30- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483643260","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483643260?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:09","pubTimestamp":1731452971,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ1L0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2483069652","title":"BUZZ-KKR-backed OneStream dips after launching stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2483069652","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483069652?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:38","pubTimestamp":1731451090,"startTime":"0","endTime":"0","summary":"BUZZ-KKR-backed OneStream dips after launching stock offering** Shares of KKR-backed finance management platform OneStream OS.O fall 2.7% to $32.60 after the bell** OS launches a public offering of 15 mln Class A shares, with 9 mln shares being offered by selling stockholders while the remaining 6 mln shares are being offered by OneStream ** Private equity firm KKR, which currently has 51.3% of voting power, is among the selling stakeholders** Meanwhile, OS is selling shares as part of a so-called \"synthetic secondary\" transaction, wherein it will sell new shares to the public and use the proceeds from that sale to repurchase its shares from KKR ** Total number of outstanding shares of common stock of OneStream will remain the same upon the offering's close - OS** Morgan Stanley, J.P. Morgan and KKR are the lead book-running managers for the proposed offering** OS went public on the Nasdaq in July at a $20 IPO price** Company has about 234.5 mln outstanding shares with a $8.05 bln mark","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL4N3MJ2E0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0267386448.USD","LU1720051108.HKD","LU1935043023.USD","LU0098860793.USD","LU1791807156.HKD","LU0314104364.USD","KKR","LU1548497426.USD","LU1363072403.SGD","IE00B3QW5Z07.USD","LU0130102774.USD","LU1935042488.USD","LU0006306889.USD","IE00B64PRP62.GBP","BK4581","LU1935042215.USD","LU1989772923.USD","LU0980610538.SGD","LU2357305700.SGD","LU1668664300.SGD","LU1720051017.SGD","BK4534","LU0225283273.USD","BK4097","BK4504","BK4585","LU0648001328.SGD","LU1989772840.SGD","IE00BZ1G4Q59.USD","LU1201861249.SGD","IE00BKVL7J92.USD","BK4135","BK4588","LU1935043536.SGD","LU1162221912.USD","LU0971096721.USD","LU1935042991.SGD","BK4127","LU1074936037.SGD","LU0106831901.USD","OS","IE00BGHQF748.EUR","LU0106261372.USD","LU0320765646.SGD"],"gpt_icon":0},{"id":"2483933063","title":"Onestream Announces Launch of Secondary Offering of Class a Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2483933063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483933063?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:58","pubTimestamp":1731448687,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA912CZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2483064201","title":"Onestream Inc - Announces Public Offering of 15 Mln Class a Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2483064201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483064201?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:58","pubTimestamp":1731448687,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA912CZP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2483065548","title":"OneStream Announces Launch of Secondary Offering of Class A Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2483065548","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483065548?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:57","pubTimestamp":1731448620,"startTime":"0","endTime":"0","summary":"BIRMINGHAM, Mich., Nov. 12, 2024 /PRNewswire/ -- OneStream, Inc.   announced today the commencement of a proposed underwritten public offering of 15,000,000 shares of its ClassA common stock, 9,006,948 shares of which are being offered by selling stockholders and 5,993,052 shares of which are being offered by OneStream as part of a non-dilutive \"synthetic secondary\" transaction . In addition, the underwriters will have a 30-day option to purchase up to an additional 2,250,000 shares of Class A common stock at the public offering price, less underwriting discounts and commissions.A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oUx5RsGnw5saWVnHBNv7ow--~B/aD01OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/bd9a73a59ba0817e4de1718b73ce75fb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oUx5RsGnw5saWVnHBNv7ow--~B/aD01OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/bd9a73a59ba0817e4de1718b73ce75fb"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onestream-announces-launch-secondary-offering-215700219.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-announces-launch-secondary-offering-215700219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","IE00BZ1G4Q59.USD","BK4504","BK4585","LU0320765646.SGD","LU1548497426.USD","LU1162221912.USD","LU0267386448.USD","BK4534","LU1720051108.HKD","LU1989772923.USD","BK4097","BK4127","LU0098860793.USD","LU1074936037.SGD","LU0106831901.USD","LU1363072403.SGD","LU1720051017.SGD","LU1668664300.SGD","LU0006306889.USD","LU2357305700.SGD","IE00BKVL7J92.USD","LU0971096721.USD","LU0106261372.USD","LU0225283273.USD","BK4516","BK4588","LU0314104364.USD","BK4581","LU1989772840.SGD"],"gpt_icon":0},{"id":"2483052245","title":"Onestream Inc Files for Offering of up to 15 Mln Shares of Class a Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483052245","media":"THOMSON REUTERS","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483052245?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:12","pubTimestamp":1731445964,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ1N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2483306510","title":"Onestream Sensible AI Library and Onestream Genesis to Improve the Strategic Impact of the Office of the CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2483306510","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483306510?lang=en_us&edition=fundamental","pubTime":"2024-11-13 02:49","pubTimestamp":1731437358,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA2DSLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2483058570","title":"OneStream Sensible AI Library and OneStream Genesis to Improve the Strategic Impact of the Office of the CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2483058570","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483058570?lang=en_us&edition=fundamental","pubTime":"2024-11-13 02:49","pubTimestamp":1731437340,"startTime":"0","endTime":"0","summary":"New capabilities for developers to speed AI solution development and adoption with purpose-built AI solutions to automate core financial workflows and pave the way for 'touchless' planning and forecasting. Sensible AI Library accelerates development of purpose-built AI with drag-and-drop features. Customers like Polaris and Stake Center Locating are using Sensible AI to automate planning and forecasting. \"Increasing business pressures are forcing business leaders to look to Finance to help them navigate change and drive growth,\" said Tom Shea, CEO at OneStream. \"Today's CFO must analyze complex data to help them look around the corners and drive strategic decision making. Sensible AI Library and Genesis will transform the way the Office of Finance approaches planning and forecasting by putting sophisticated and rapid data analysis into the hands of senior finance leaders and their teams.\"","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oUx5RsGnw5saWVnHBNv7ow--~B/aD01OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/bd9a73a59ba0817e4de1718b73ce75fb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oUx5RsGnw5saWVnHBNv7ow--~B/aD01OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/bd9a73a59ba0817e4de1718b73ce75fb"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onestream-sensible-ai-library-onestream-184900216.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-sensible-ai-library-onestream-184900216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","OS"],"gpt_icon":1},{"id":"2482086286","title":"Visage Transforms Imaging to the Cloud at RSNA 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482086286","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482086286?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:34","pubTimestamp":1731422040,"startTime":"0","endTime":"0","summary":"Visage innovates with Visage Chat, Visage 7 | AI and more. Visage continues to demonstrate leadership in Healthcare Imaging's move to the cloud. Visage 7 CloudPACS is the industry's benchmark for speed, delivering images faster and more securely than on-premise and legacy hybrid cloud PACS. Over the past four years, 100% of Visage's new PACS customers have been implemented in the cloud. Based on two years of customer interviews, Visage is pleased to announce the new informative whitepaper: \"Progress Towards Cloud: Relief, Considerations and New Opportunities,\" authored by Signify Research's Amy Thompson, Research Manager. This has been supplemented by The Imaging Wire video interview: \"The Road to Cloud-Based PACS\".Visage Ease VP. As a work-in-progress, Visage will be demonstrating immersive 3D Key Views and Pass Through Mode for the Apple Vision Pro. Using a new finger-tap gesture, users can easily navigate through multiple pre-saved immersive 3D perspectives with different orientatio","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ah2JQ_9AwP2pNKF4yvQzuA--~B/aD0yMzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4b012437a97358117b6beae01c74b4d8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ah2JQ_9AwP2pNKF4yvQzuA--~B/aD0yMzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4b012437a97358117b6beae01c74b4d8"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/visage-transforms-imaging-cloud-rsna-143400601.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/visage-transforms-imaging-cloud-rsna-143400601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4097","PME.AU","BK7094","OS"],"gpt_icon":0},{"id":"2482570824","title":"Press Release: IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2482570824","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482570824?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:05","pubTimestamp":1731413100,"startTime":"0","endTime":"0","summary":"therapeutic cancer vaccine IO102-IO103 in combination with Merck's. melanoma on track with primary endpoint of progression free survival.  projected to be reached in first half of 2025. -- Primary endpoint met in Phase 2 basket trial  cohort. evaluating IO102-IO103 in combination with pembrolizumab in the. first-line treatment of advanced squamous cell carcinoma of the head and. treatment of patients with resectable melanoma or SCCHN is proceeding. equivalents; the company continues to expect its cash position will. support operations into the fourth quarter of 2025. Dr. Zocca continued, \"Our T-win platform generates off-the-shelf therapeutic cancer vaccine candidates with a unique mechanism of action, capable of both targeting immune-suppressive cells and cancer cells. This dual action is what drives the strong activity we see when we combine IO102-IO103 with an anti-PD-1 therapy. In addition to IO102-IO103, the T-win platform has generated other novel candidates including IO112, targ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","R","BK4559","IE00BSNM7G36.USD","LU0238689110.USD","LU0965509101.SGD","SITC","LU1934455863.HKD","IE000M9KFDE8.USD","LU0266013472.USD","LU1116320901.HKD","BK4571","LU1037948897.HKD","LU1585245621.USD","LU1093756168.USD","DRR","LU1093756325.SGD","BK4231","IO","OS","PFS","BK4548","LU1066053197.SGD","01698","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU1066051498.USD","LU0058720904.USD","LU0320765489.SGD","TME","IE00BLSP4239.USD","LU1934455277.USD","BK4022","IE00B2B36J28.USD","BK4526","LU0211331839.USD","IE0009355771.USD","LU0265550359.USD","IE00BLSP4452.SGD","BK4108","LU2039709279.SGD","IOBT","IE00BYTNYN87.SGD","LU1037948541.HKD","IE00BBT3K403.USD","BK4550","BK4195","LU0208291251.USD","MRK"],"gpt_icon":0},{"id":"2482705564","title":"Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2482705564","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482705564?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"First-of-its-kind study of >1K patients evaluating the impact of adjuvant treatment escalation in patients tested with Signatera; results to be presented at ASCO GI in Jan. 2025. AUSTIN, Texas, November 12, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced the completion of a study using Signatera from the CALGB /SWOG 80702 randomized, phase III clinical trial. CALGB /SWOG 80702 evaluated the benefit of adding celecoxib to FOLFOX in postoperative treatment of stage III colorectal cancer  in a biomarker unselected population.This pre-specified analysis includes 1,011 CRC patients with available post-surgical plasma samples and investigates Signatera’s ability to identify a subgroup of patients who may benefit from adding celecoxib to FOLFOX. Disease free survival  and overall survival  are the study’s primary and secondary endpoints, respectively.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rOU9or26IPqqszSyfBCoOA--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3571081993d629c81146f097d5735c59","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rOU9or26IPqqszSyfBCoOA--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3571081993d629c81146f097d5735c59"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-completion-signatera-analysis-120000221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4166","OS","BK4134","WRD","LU1861217088.USD","LU2065170008.USD","LU0456854461.SGD","CRC","LU2065169927.USD","BK4139","III","LU2065171402.SGD","DFS","LU2360107671.USD","LU0266512127.USD","LU0106831901.USD","NTRA","BK4213","CLIA","BK4097","LU2065731478.USD","LU2065171311.SGD","LU0053671581.USD","BK4588","LU1668664300.SGD","LU1791807156.HKD","LU1861220207.SGD","BK4585"],"gpt_icon":0},{"id":"2482570384","title":"Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2482570384","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482570384?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients  –。– 47%  ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population –。– Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events –。– Results highlight consistency of revumenib's compelling clinical profile –。– Syndax to host a conference call today at 8:00 am ET –。WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals , a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or refractory (R/R) mutant NPM1  acute myeloid leukemia  cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor.The AUGMENT-101 Phase 2 protocol-defined efficacy evaluable population included 64 adult patients with R/R mNPM1 AML. The","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HRoj.7n3nL7v6oAemvs4dg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/004365bc164539de8f2b6fa15e8cd147","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HRoj.7n3nL7v6oAemvs4dg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/004365bc164539de8f2b6fa15e8cd147"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/syndax-announces-positive-pivotal-topline-120000074.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-announces-positive-pivotal-topline-120000074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNDX","LU1699723380.USD","ALL","BK4588","BK4585","LU2463526074.USD","LU0985320562.USD","BK4139","LU2355687059.USD","OS","HSCT","BK4109","LU1571399168.USD","BK4533","CR","BK4097","BK4161","BK4107","ASH"],"gpt_icon":0},{"id":"2482740083","title":"Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2482740083","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482740083?lang=en_us&edition=fundamental","pubTime":"2024-11-12 15:00","pubTimestamp":1731394800,"startTime":"0","endTime":"0","summary":"Daiichi Sankyo and AstraZeneca’s new application is based on the TROPION-Lung05 phase 2 trial and supported by data from additional trials including TROPION-Lung01. Previously submitted BLA based on TROPION-Lung01 phase 3 trial for patients with nonsquamous NSCLC has been voluntarily withdrawn. TOKYO & BASKING RIDGE, N.J., November 12, 2024----Daiichi Sankyo  and AstraZeneca  have submitted a new Biologics License Application  for accelerated approval in the U.S. for datopotamab deruxtecan  for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated  non-small cell lung cancer  who have received prior systemic therapies, including an EGFR-directed therapy.Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.\"Treating EGFR-mutated non-small cell lung cancer is incredibly challenging following disease pr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PQtImeMlNxA2wqoBrgTffg--~B/aD01MDA7dz0yMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/867d413bf16e2a4954b2377671109f13","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PQtImeMlNxA2wqoBrgTffg--~B/aD01MDA7dz0yMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/867d413bf16e2a4954b2377671109f13"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-bla-submitted-accelerated-070000417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSNKY","IE0031619046.USD","AEIS","BK4097","BK4007","OS","BK4157","BK4211","IE00B66KJ199.SGD","IE00B7SZL793.SGD","PFS","IE00B19Z4B17.USD","BK4195","PBD","ADC","BK4080","DSKYF","BK4231"],"gpt_icon":0},{"id":"2482765517","title":"HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker","url":"https://stock-news.laohu8.com/highlight/detail?id=2482765517","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482765517?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359100,"startTime":"0","endTime":"0","summary":"Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell respo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/11/2978565/0/en/HOOKIPA-Pharma-s-Eseba-vec-Highlighted-in-SITC-Late-Breaker.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","HOOK","IE00BYTNYN87.SGD","BK1103","IE00B12V2V27.USD","BK4097","BK4211","SG9999011746.SGD","01308","BK4139","BK4505","WRD","BK1541","BK4195","PFS","IE00BYQNZ168.SGD"],"gpt_icon":0},{"id":"1150638090","title":"Stock Track | Onestream Inc Soars as HarmonyOS Gains Traction in China's Software Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1150638090","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150638090?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:48","pubTimestamp":1731336531,"startTime":"0","endTime":"0","summary":"Shares of Onestream Inc , a leading provider of corporate performance management software solutions, surged 5.13% on Friday, November 11th, 2024, amid growing concerns over Android's declining market share in China and the rise of Huawei's HarmonyOS.According to a report by Tech Insights, Android's market share in China dropped from 72% to 70% in the third quarter of 2024 compared to the same period last year. On the other hand, Huawei's HarmonyOS saw its market share increase from 13% to 15% du","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Onestream Inc Soars as HarmonyOS Gains Traction in China's Software Market","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["OS"],"gpt_icon":0},{"id":"2482053200","title":"Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482053200","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482053200?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, Nov. 11, 2024  -- Can-Fite BioPharma Ltd.  , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces the dosing of the first patient in the Phase IIa clinical trial in patients with advanced pancreatic adenocarcinoma .“We are excited to have the first patient enrolled and hope that we will be able to demonstrate the safety and efficacy of Namodenoson in the pancreatic cancer patient population. This trial provides us the opportunity to explore our innovative treatment approach for patients who are facing significant gaps in effective treatment options,” stated Dr. Michael Silverman, Can-Fite’s Medical Officer.Can-Fite BioPharma Ltd.   is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenos","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sJtGBGhYav13.OX82J5L2A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6114327b6294df8bacb7f8b771866c2b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sJtGBGhYav13.OX82J5L2A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6114327b6294df8bacb7f8b771866c2b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fite-achieves-milestone-first-patient-120000494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BK4097","BK4195","HCC","BK4211","BK4181","BK4218","CANF","BK4139","OS","PFS","PK"],"gpt_icon":0},{"id":"2482737616","title":"IMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482737616","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482737616?lang=en_us&edition=fundamental","pubTime":"2024-11-11 18:00","pubTimestamp":1731319200,"startTime":"0","endTime":"0","summary":"Preparations Underway for Phase 3 Ovarian Cancer Trial; Set to Initiate in 1Q25. Imunon, Inc.  previously reported positive topline results from the Phase 2 OVATION 2 trial of IMNN-001 in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin -12 plasmid that allows for targeted expression of IL-12 to avoid toxicities and poor pharmacokinetics of systemically administered IL-12.As of September 30, 2024, Imunon had approximately $10.3 million in cash, cash equivalents, investments, and interest receivable. We estimate that the company has sufficient capital to fund operations into the third quarter of 2025. Imunon currently has approximately 14.5 million common shares outstanding and, when factoring in stock options and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imnn-meeting-fda-preparation-phase-100000450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","IMNN","BK4139","OS"],"gpt_icon":0},{"id":"2482451317","title":"OneStream Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482451317","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482451317?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:47","pubTimestamp":1731102443,"startTime":"0","endTime":"0","summary":"* OneStream Inc    reported quarterly adjusted earnings of 55 cents per share for the quarter ended September 30.  The mean expectation of fourteen analysts for the quarter was for breakeven results p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"OneStream Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.onestream.com","stockEarnings":[{"period":"1week","weight":0.1797},{"period":"1month","weight":0.1524},{"period":"3month","weight":0.2475},{"period":"6month","weight":0.7165},{"period":"ytd","weight":0.7165}],"compareEarnings":[{"period":"1week","weight":0.0508},{"period":"1month","weight":0.0331},{"period":"3month","weight":0.1046},{"period":"6month","weight":0.1302},{"period":"1year","weight":0.3589},{"period":"ytd","weight":0.2597}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Onestream Inc","nameEN":"Onestream Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Onestream Inc(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Onestream Inc(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Onestream Inc,OS,Onestream Inc股票,Onestream Inc股票老虎,Onestream Inc股票老虎国际,Onestream Inc行情,Onestream Inc股票行情,Onestream Inc股价,Onestream Inc股市,Onestream Inc股票价格,Onestream Inc股票交易,Onestream Inc股票购买,Onestream Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Onestream Inc(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Onestream Inc(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction